ARID1A and neoplasm: To further advance our understanding of why ARID1A mutations arise in both early and late tumor development, we generated and evaluated three stable bladder (cancer) cell line models and additionally one transient model, i.e., two normal‐like (UROtsa, HBLAK) and two malignant (T24, JMSU‐1) models.